Oncocyte Corporation (OCX) News

Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the...

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in...

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision...

Form 8-K - Current report

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics...

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

- Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Oncocyte Reports Third Quarter 2023 Financial Results

-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00...

Oncocyte to Announce Third Quarter 2023 Financial Results

IRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report